{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:11:05Z","timestamp":1777414265948,"version":"3.51.4"},"reference-count":5,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA097186"],"award-info":[{"award-number":["P50CA097186"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266452"],"award-info":[{"award-number":["R01CA266452"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The androgen receptor (AR) is the most important therapeutic target for metastatic prostate cancer. Though clinical responses to AR inhibition are nearly universal, so is progression, usually accompanied by reactivation of AR signaling. A new small-molecule dual AR degrader\/inhibitor shows promise in overcoming resistance and improving clinical outcomes.<\/jats:p>\n                  <jats:p>See related article by Nayak et al., p. 224<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-25-3045","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:20:45Z","timestamp":1761754845000},"page":"13-15","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle"],"prefix":"10.1158","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9531-3658","authenticated-orcid":false,"given":"Michael D.","family":"Nyquist","sequence":"first","affiliation":[{"name":"1Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"2Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5726","authenticated-orcid":false,"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"1Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"2Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026010603065546200_bib1","first-page":"224","article-title":"Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader and antagonist, for the treatment of advanced prostate cancer","volume":"32","author":"Nayak","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026010603065546200_bib2","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"key":"2026010603065546200_bib3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol Cell Proteomics"},{"key":"2026010603065546200_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann Oncol"},{"key":"2026010603065546200_bib5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-25-3045\/3666741\/ccr-25-3045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-25-3045\/3669003\/ccr-25-3045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/32\/1\/13\/3721742\/ccr-25-3045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/32\/1\/13\/3721742\/ccr-25-3045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:07:05Z","timestamp":1767686825000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/32\/1\/13\/771270\/Targeting-the-Androgen-Receptor-Pathway-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-3045","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}